GlassScriptPhysician profile
Samir K Ballas
NPI 1356375372
$16,478.07
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $7,378 · 2020: $6,160 · 2021: $2,940.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $6,160.00 | 2020 | |
| Pfizer INC. | $5,625.00 | 2019 | |
| Csl Behring | $2,940.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,502.23 | 2019-2022 | |
| Terumo Bct, INC. | $103.02 | 2019 | |
| Eusa Pharma (US) LLC | $61.77 | 2019 | |
| Genentech USA, INC. | $48.05 | 2019 | |
| Agios Pharmaceuticals, INC. | $38.00 | 2019-2022 |
Research and ownership
$83,311.67 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Ballas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.